| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Chemotherapy National Service Center [W. D. DeW., A. G.], and Biometry Branch, [N. M.], National Cancer Institute, Bethesda, Maryland 20014
Hematological recovery after a large dose of cyclophosphamide was characterized by early rapid recovery of marrow stem cells (colony-forming assay), followed successively by recovery of circulating stem cells (colony-forming assay), total marrow cellularity, and circulating blood cells. This recovery sequence provided a model in which marrow with different proliferative rates could be studied for sensitivity to cyclophosphamide by subjecting animals to a second treatment at various intervals after an initial treatment. The results of this type of study suggest that the proliferative state of a cell population is a determinant of sensitivity to cyclophosphamide.
1 This study was supported in part by Contract PH 43-64-91 from the Cancer Chemotherapy National Service Center. A preliminary report has been presented (10).
2 To whom reprint requests should be sent at the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, N. Y. 14620.
Received 11/10/69. Accepted 2/ 3/70.
This article has been cited by other articles:
![]() |
K. Kusano, S. Ebara, K. Tachibana, T. Nishimura, S. Sato, T. Kuwaki, and T. Taniyama A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factor Blood, February 1, 2004; 103(3): 836 - 842. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |